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Abstract: In people, the antifibrinolytic drug tranexamic acid reduces bleeding and the need for blood
products with both normal and exaggerated fibrinolysis without increasing the number of thromboem-
bolic events. In dogs, in addition to prevention and treatment of bleeding, higher doses of tranexamic
acid can be used to induce vomiting. The objective of this study was to evaluate the effect of a high dose
of tranexamic acid on the coagulation of healthy Beagle dogs. A prospective trial was conducted in eight
healthy Beagles receiving tranexamic acid for a concurrent trial evaluating different antiemetics. Rota-
tional thromboelastometry (ROTEM) analysis (EXTEM, APTEM, FIBTEM, INTEM) was performed
before and 30 minutes after intravenous administration of 50 mg/kg tranexamic acid. ROTEM parame-
ters before and after tranexamic acid administration and between EXTEM and APTEM were compared
with Wilcoxon matched-pairs signed rank test and data is presented as median (range). After tranexamic
acid administration, FIBTEM clotting time became significantly shorter (p=0.03) from 37 s (28-124 s) to
33 s (27-40 s) and INTEM clot formation time significantly decreased (p=0.02) from 82 s (47-132 s) to 60
s (43-107 s). After tranexamic acid APTEM MCF was significantly weaker (p=0.01) with 45 mm (30-63
mm) than EXTEM MCF with 55 mm (43-69 mm) and than APTEM MCF before tranexamic acid with
55 mm (43-69 mm) (p=0.02). All other analysed parameters including maximum lysis did not change
after administration of tranexamic acid. The administration of 50 mg/kg intravenous tranexamic acid
resulted in small changes in ROTEM profiles without inducing a hypercoagulable clot. In conclusion,
tranexamic acid can safely be administered to healthy dogs with normal coagulation profiles. As an
additional finding, APTEM parameters measured in the current study do not support the use of this test
in dogs
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In people, the antifibrinolytic drug tranexamic acid re-
duces bleeding and the need for blood products with 
both normal and exaggerated fibrinolysis without in-
creasing the number of thromboembolic events. In 
dogs, in addition to prevention and treatment of bleed-
ing, higher doses of tranexamic acid can be used to in-
duce vomiting. The objective of this study was to eval-
uate the effect of a high dose of tranexamic acid on the 
coagulation of healthy Beagle dogs. 
A prospective trial was conducted in eight healthy Bea-
gles receiving tranexamic acid for a concurrent trial 
evaluating different antiemetics. Rotational thromboe-
lastometry (ROTEM) analysis (EXTEM, APTEM, 
FIBTEM, INTEM) was performed before and 30 min-
utes after intravenous administration of 50 mg/kg 
tranexamic acid. ROTEM parameters before and after 
tranexamic acid administration and between EXTEM 
and APTEM were compared with Wilcoxon matched-
pairs signed rank test and data is presented as median 
(range). 
After tranexamic acid administration, FIBTEM clotting 
time became significantly shorter (p=0.03) from 37 s 
(28-124 s) to 33 s (27-40 s) and INTEM clot formation 
time significantly decreased (p=0.02) from 82 s (47-
132 s) to 60 s (43-107 s). After tranexamic acid APTEM 
MCF was significantly weaker (p=0.01) with 45 mm 
(30-63 mm) than EXTEM MCF with 55 mm (43-69 mm) 
and than APTEM MCF before tranexamic acid with 
55 mm (43-69 mm) (p=0.02). All other analysed param-
eters including maximum lysis did not change after 
administration of tranexamic acid. 
The administration of 50 mg/kg intravenous tranexam-
ic acid resulted in small changes in ROTEM profiles 
without inducing a hypercoagulable clot. In conclusion, 
Wirkung von 50 mg/kg intravenös 
verabreichter Tranexamsäure auf die 
Blutgerinnung, beurteilt durch Rota-
tions-Thromboelastometrie (ROTEM) 
bei gesunden Beagle-Hunden
Der antifibrinolytische Wirkstoff Tranexamsäure redu-
ziert beim Menschen Blutungen und den Bedarf an 
Blutprodukten, dies sowohl bei normaler als auch bei 
übertriebener Fibrinolyse und ohne die Anzahl der 
thromboembolischen Ereignisse zu erhöhen. Bei Hun-
den können höhere Dosen von Tranexamsäure neben 
der Vorbeugung und Behandlung von Blutungen auch 
zur Induktion von Erbrechen verwendet werden. Ziel 
dieser Studie war es, die Wirkung einer hohen Dosis 
Tranexamsäure auf die Koagulation von gesunden 
 Beagle-Hunden zu bewerten.
Die prospektive Studie wurde bei acht gesunden Beagles 
durchgeführt, die Tranexamsäure während einer Studie 
zur Bewertung verschiedener Antiemetika erhielten. 
Rotations-Thromboelastometrie (ROTEM) Analyse 
(EXTEM, APTEM, FIBTEM, INTEM) wurde vor und 
30 Minuten nach intravenöser Verabreichung von 
50 mg/kg Tranexamsäure durchgeführt. Die ROTEM- 
Parameter vor und nach der Verabreichung von Tra-
nexamsäure und zwischen EXTEM und APTEM wur-
den mit dem Wilcoxon-Matched-Pair-Test verglichen 
und der Medianwert (Range) angegeben.
Nach der Verabreichung von Tranexamsäure wurde die 
Gerinnungszeit von FIBTEM von 37 s (28-124 s) auf 33 s 
(27-40 s) signifikant verkürzt (p = 0,03) und die Bildung 
der INTEM-Gerinnsel reduzierte sich signifikant (p = 
0,02) von 82 s ( 47-132 s) auf 60 s (43-107 s). Nach Tra-
nexamsäure war APTEM MCF mit 45 mm (30-63 mm) 
signifikant schwächer (p = 0,01) als EXTEM MCF mit 
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Introduction 
Fibrinolysis is a physiologic mechanism leading to the 
breakdown of a blood clot once the endothelium has 
healed. Plasminogen is converted by tissue plasminogen 
activator (tPA) or urokinase to plasmin. Plasmin adheres 
to the lysine binding site on fibrin and enzymatically 
breaks down the fibrin strands of the clot, which gener-
ates fibrin degradation products1. 
Too early and/or exaggerated fibrinolysis (defined as 
hyperfibrinolysis) is pathologic and can cause bleed-
ing12. Hyperfibrinolysis has been reported in dogs with 
haemoabdomen6, 25, ascites with or without right sided 
heart failure28, 29, A. vasorum infection24, trauma20, liver 
disease7, 25 and neoplasia25. 
Tranexamic acid (TXA) is a synthetic lysine analogue 
that blocks fibrinolysis by preventing the binding of 
plasmin to fibrin11. In dogs infected with A. vasorum24 
and after trauma20, TXA was able to inhibit hyperfi-
brinolysis. A recent study in dogs22 showed that 
20 mg/kg intravenous (IV) TXA resulted during 6 hours 
in plasma levels that were formerly reported to be effec-
tive to inhibit in vitro hyperfibrinolysis5. In addition to 
inhibition of hyperfibrinolysis, administration of TXA 
in people with or without a diagnosis of hyperfibrinol-
ysis reduced the need for blood products10 and decreased 
mortality2, 23. In dogs, only one retrospective study eval-
uating the effect of TXA at a dose of 5.9–16.5 mg/kg IV 
is available15. Both mortality and the total number of 
blood products administered were lower when bleeding 
dogs receiving TXA with (n = 38) and without (n = 30) 
blood product administration were compared to bleed-
ing dogs receiving blood products without TXA (n = 
62). However, when only the dogs receiving blood with 
TXA were compared to the dogs receiving blood without 
TXA no difference could be found. Tranexamic acid 
induces vomiting if administered fast and/or in high 
dosages and has therefore been recommended as an 
emetic agent in dogs13. A starting dose of 50 mg/kg of 
TXA IV is currently recommended to induce vomiting 
in dogs21. 
Potentially, TXA administration could lead to 
 thromboembolism. In people, the use of TXA has 
not increased the occurrence of thromboembolic 
events23. 
The objective of this study was to evaluate the effect of 
50 mg/kg IV TXA on ROTEM parameters of healthy 
dogs. 
The hypothesis was that a high dose of TXA does not 
induce clinically relevant procoagulatory effects in 
healthy dogs. Because viscoelastic coagulation testing 
allows for fast visual inspection of clot formation, 
 stability and lysis18, rotational thromboelastometry 
(ROTEM) was chosen to assess the effects of TXA on 
coagulation. 
Materials and Methods 
The project was approved by the Committee for Animal 
Experimentation of the Canton Zurich, Switzerland 
(191/2016). Eight healthy Beagle dogs (4 intact females, 
4 intact males), aged 6.5 (6-6.5) years old (median 
(range)), and weighing 13.1 kg (10.7-16.6 kg) were includ-
ed in the study. The dogs were judged to be healthy 
based on history, physical examination and blood anal-
ysis (packed cell volume, total plasma protein and ve-
tranexamic acid can safely be administered to healthy 
dogs with normal coagulation profiles. As an addition-
al finding, APTEM parameters measured in the current 
study do not support the use of this test in dogs. 
Keywords: Antifibrinolytic, canine, emetic, tranexamic acid, 
viscoelastic coagulation test, vomiting
55 mm (43-69 mm) und als APTEM MCF vor Tranexam-
säure mit 55 mm (43-69 mm) (p = 0,02). Alle anderen 
analysierten Parameter einschließlich der maximalen 
Lyse änderten sich nach Verabreichung von Tranexam-
säure nicht.
Die Verabreichung von 50 mg/kg intravenöser Tra-
nexamsäure führte zu kleinen Änderungen der  ROTEM- 
Profile, ohne ein hyperkoagulierbares Gerinnsel zu in-
duzieren. Zusammenfassend kann Tranexamsäure ge-
sunden Hunden mit normalen Gerinnungsprofilen si-
cher verabreicht werden. Als zusätzliches Ergebnis der 
aktuellen Studie konnten die gemessenen APTEM-Pa-
rameter die Verwendung dieses Tests bei Hunden nicht 
bestätigen. 
Schlüsselwörter: Antifibrinolytikum, Hund, Emetika, 
Tranexamsäure, viskoelastischer Gerinnungstest,  
Erbrechen
369_376_Kutter.indd   370 24.05.19   11:52
Originalarbeiten | Original contributions
371SAT | ASMV 6 | 2019Band 161, Heft 6, Juni 2019, 369–376, © GST | SVS
Effect of 50 mg/kg intrave-
nous tranexamic acid on 
coagulation assessed by 
rotational thromboelasto-
metry (ROTEM) in healthy 
Beagle dogs
A. P. N. Kutter et al.
nous blood gas analysis (RAPIDPoint 500 Blood Gas 
System, Siemens Healthcare AG, Freilagerstrasse 40, 
8047 Zürich, Switzerland). The dogs lived in groups of 
4 dogs in a research facility and were under regular su-
pervision by two trained animal keepers. 
The current work was performed during a blinded ran-
domized crossover trial evaluating the efficacy of ma-
ropitant and ondansetron versus placebo against 
TXA-induced nausea and vomiting14. The dogs were 
given all three treatments with a wash-out period of 
3 weeks between trials. On the days where the animals 
were scheduled to receive the placebo treatment, the 
effect of TXA on viscoelastic coagulation tests was as-
sessed with the following protocol. A baseline blood 
sample (“before TXA”) was collected from the V. jugu-
laris with a 20 G needle and a 5 ml syringe and was 
transferred into two 1.3 ml tubes containing 3.2% so-
dium citrate (Sarstedt AG, Bahnweg Süd 36, 9475 Seve-
len, Switzerland). 
Immediately thereafter the dogs received 3 ml 0.9% 
NaCl solution IV through a 22 G cephalic vein catheter 
(Surflo IV catheter, Terumo, Bodenäckerstrasse 3, 8957 
Spreitenbach, Switzerland) followed 10 minutes later by 
50 mg/kg TXA IV (Tranexam OrPha®; OrPha Swiss-
GmbH, Untere Heslibachstrasse 41A, 8700 Küsnacht, 
Switzerland) administered over 2 minutes. Nausea and 
vomiting was monitored as described by Kantyka et al.14. 
Thirty minutes after the end of administration of TXA 
a second whole blood sample (“after TXA”) was collect-
ed as described above. The blinded observer assessing 
nausea and vomiting (MK) left the room during the 
possible blood sampling times during all trials. 
ROTEM analysis 
The ROTEM profiles were analysed with a ROTEM 
delta® (Axon Lab AG, Täfernstrasse 15, 5405 Baden, 
Switzerland) before and 30 minutes after administration 
of TXA. The citrated samples were kept in the dedicated 
warming pit of the ROTEM device until analysis was 
performed. Pipetting was performed with the automat-
ed pipet of the device adding 300 µL of citrated blood 
to the reagent. Analysis was performed at 37 °C for 
60 minutes. 
Lyophilized single reagents were used to evaluate differ-
ent parts of the coagulation cascade at the same time in 
the four measurement channels. The extrinsic pathway 
was evaluated with the EXTEM test, which contains 
recombinant human tissue factor, phospholipids and 
calcium chloride. The fibrin clot was assessed with 
FIBTEM, a test that contains the EXTEM reagents with 
the addition of cytochalasin D to inactivate the platelets 
present in the whole blood sample. The APTEM test 
was developed to assess hyperfibrinolysis in vitro. The 
APTEM test combines EXTEM and the antifibrinolyt-
ic drug aprotinin leading to faster/stronger APTEM 
parameters compared to EXTEM parameters, if hyper-
fibrinolysis is present. The intrinsic pathway was as-
sessed with the INTEM test. It contains ellagic acid, 
partial thromboplastin, phospholid and calcium chlo-
ride. 
The following parameters were evaluated in the current 
study: Clotting time (CT) is the time in seconds from 
activation of the sample until a first clot with the defined 
amplitude of 2 mm is built. It is dependent on the ac-
tivity of the clotting factors. EXTEM CT and INTEM 
CT correlate to PT and aPTT, respectively4. 
Clot formation time (CFT) is the time in seconds meas-
ured from the end of CT (2 mm) until an amplitude of 
20 mm is reached. 
Maximum clot firmness (MCF) is the maximum ampli-
tude displayed in mm that is reached during the 60 min-
utes of measurement time. The MCF in the platelet-con-
taining test (all but FIBTEM) is dependent on both 
fibrin and platelet concentration and function.
Maximum lysis (ML) is the relative amount of lysis 
measured in percent during the measurement time of 
60 minutes. 
Statistical analysis 
The sample size was calculated for the project evaluating 
antiemetics14 and eight dogs entered the study. A com-
mercially available software (Graphpad Prism, GraphPad 
Software, 2365 Northside Drive, San Diego, CA 92108, 
USA) was used for analysis. After normality testing with 
the Shapiro-Wilk test, a Wilcoxon matched-pairs signed 
rank test was performed to compare ROTEM parameters 
before and after TXA treatment, between EXTEM and 
APTEM at each time point and to compare the time lag 
between blood collection and beginning of ROTEM 
analysis. The significance level was set at p < 0.05. 
Results 
All eight dogs completed the study. ROTEM parameters 
before and after administration of TXA are summarized 
in Table 1. FIBTEM CT (Figure 1) and INTEM CFT 
were significantly shorter (p = 0.03 and p = 0.02, respec-
tively) and APTEM MCF was significantly smaller (p = 
0.02) after TXA administration. While EXTEM and 
APTEM MCF were similar at baseline, APTEM MCF 
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was smaller than EXTEM MCF (p = 0.01) after TXA 
administration. All other analysed parameters including 
maximum lysis did not change after administration of 
TXA.
Baseline samples were analysed within 9 (6 to 56) min-
utes (median (range)), which was a significantly shorter 
time period (p = 0.01) in comparison to the one of the 
samples after TXA administration that were analysed 
within 48 (27 to 110) minutes.
Discussion 
The intravenous administration of 50 mg/kg TXA re-
sulted in small statistically significant changes in early 
ROTEM parameters, but no changes in clot firmness 
and no hypercoagulable ROTEM tracings were found 
in this study in healthy dogs.
Doses currently used in dogs to treat bleeding diathesis 
with or without hyperfibrinolysis range from 10 - 80 mg/
kg IV16, 24. A starting dose of 50 mg/kg IV has been rec-
ommended to induce vomiting in dogs13, 21. Dogs that 
are given drugs to induce vomiting are typically not 
expected to suffer from hyperfibrinolysis or hypocoag-
ulability. The administration of a high dose of an anti-
fibrinolytic drug as an emetic may therefore potentially 
lead to hypercoagulability and thrombotic events. In 
the current study, the use of 50 mg/kg TXA IV did not 
lead to increased clot firmness (a measure of hyperco-
Table 1: Clotting time (CT), clot formation time (CFT), maximum clot firmness (MCF) and maximum lysis (ML) measured 
with rotational thromboelastometry (ROTEM) using different activators for the evaluation of the extrinsic pathway (EXTEM), 
the fibrinogen clot (FIBTEM), hyperfibrinolysis with the addition of aprotinin (APTEM) and the intrinsic pathway (INTEM) 
before and after tranexamic acid (TXA). 
Before TXA In – House
Reference Range
After TXA
Median Range Median Range
EXTEM        
CT (s) 42 30–83 23–87 36 27–73
CFT (s) 119 62–203 85–357 145 65–260
MCF (mm) 58 46–69 32–65 55§ 43–69
ML (%) 0 0 -10 0–12 2 0–15
FIBTEM          
CT (s) 37 28–124 21–112 33* 27–40
MCF (mm) 6.5 3–12 2–9 5.5 5–10
ML (%) 17 0–78 1–99 30 0–99
APTEM          
CT (s) 36 28–78 21–75 36 28–93
CFT (s) 141 76–241 99–485 184 65–411
MCF (mm) 55 43–69 32–63 45*,§ 30–63
ML (%) 2 0–7 0–10 2.5 0–10
INTEM          
CT (s) 118 86–151 133–210 129 97–136
CFT (s) 82 47–132 59–201 60* 43–107
MCF (mm) 62 55–73 52–71 65 54–71
ML (%) 0.5 0–3 0–3 0 0–5
* marks statistical significant changes before and after TXA, § marks statistical significant differences between MCF EXTEM 
and APTEM. Values out of reference range are marked in bold.
Figure 1: Box and whiskers plot showing fibrinogen specific thromboelastometry 
(FIBTEM) clotting time (CT) results in seconds of all individual dogs before and after 
tranexamic acid (TXA). The asterix shows a statistically significant change and the in-
house reference range is shaded in grey.
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agulability). This is supported by the fact that, compared 
to people, dogs lyse clots earlier than people5, 19. In a 
research study that used dogs as a model for pulmonary 
thromboembolism, a very high dose of TXA (110 mg/
kg per os twice daily) was necessary to stabilise throm-
bin-induced clots and to prevent their complete lysis 
within hours19. Another study directly compared throm-
boelastography (TEG) parameters in people and dogs 
and found that 10 times higher TXA plasma levels were 
necessary to inhibit in vitro induced hyperfibrinolysis in 
dogs5. Based on these studies, dogs seem to be able to 
very effectively induce fibrinolysis. 
The administration of 50 mg/kg TXA IV shortened the 
CT only in FIBTEM but not in EXTEM. Earlier work 
with 10 mg/kg IV TXA followed by a infusion of 
10 mg/kg infusion over three hours showed that the R 
time in tissue factor activated TEG (similar to CT 
 EXTEM) was reduced from 3.3 (± 0.6) (mean (SD)) to 
2.7 (± 0.8) minutes (p = 0.05)16. However, in a more 
recent study, tissue factor activated R time was not 
changed after 20 mg/kg IV TXA22. 
In the current study CFT was only significantly short-
ened in the INTEM profile after the administration of 
TXA. Comparison with the earlier mentioned studies 
evaluating the effect of 10 and 20 mg/kg TXA, respec-
tively, is not possible as they did not test the intrinsic 
activation. The concentration and activity of clotting 
factors and/or platelets influencing CT and CFT should 
theoretically not be influenced by the administration of 
TXA. In the population of healthy dogs used in this 
study, two dogs showed an abnormally high FIBTEM 
CT that normalized after TXA (Figure 1), which may 
be a sign of subtle early fibrinolysis in these dogs. In the 
FIBTEM test the platelets are inactivated and the weak 
fibrin clot is less resistant to fibrinolysis9. The fact that 
EXTEM CT, which should theoretically be identical to 
FIBTEM CT, was not prolonged supports this explana-
tion. In earlier studies in clinical patients, we suspected 
that a non-forming FIBTEM clot (MCF of 2 mm) might 
also be a sign for activated fibrinolysis and not only for 
hypofibrinogenemia24, 25. However, why the CFT results 
of the intrinsically activated test were shortened cannot 
be answered with the current study. 
In the current study in dogs, the APTEM MCF in RO-
TEM was weaker after the administration of TXA com-
pared to both APTEM baseline and to EXTEM after 
TXA. This is an unexpected finding questioning the use 
of APTEM in dogs. A weaker APTEM than EXTEM 
clot has been observed before in bleeding dogs25 and 
during the collection of reference values in 48 healthy 
dogs analysed within 20-30 minutes after blood collec-
tion with samples stored at 37 °C prior to analysis. 
( Jud Schefer R, personal communication). Similar to 
this, we reported previously that APTEM results in cats 
were not stronger but more prone to an artefact called 
clot retraction compared to EXTEM results17. In people, 
the APTEM test was developed to detect hyperfibrinol-
ysis in vitro by adding aprotinin to the probe. Aprotinin 
also inhibits fibrinolysis and should lead to a stronger 
APTEM profile compared to the EXTEM profile. How-
ever, in people, APTEM was not able to detect hyperfi-
brinolysis earlier than with EXTEM clot firmness 
alone3. Based on these results, APTEM results should 
be interpreted with caution in dogs and additional stud-
ies investigating the usefulness and reliability of APT-
EM profiles to detect hyperfibrinolysis are required.
Limitations
The present study has several limitations. 
Firstly, the blood samples collected before administra-
tion of TXA were analysed within shorter time than 
those after TXA. The second time point was planned 
only 30 minutes after drug administration in order to 
have a maximal effect of TXA on ROTEM parameters. 
Blood kept at room temperature became more hyperco-
agulable if stored between 30 and 120 minutes in a study 
performed with citrated canine blood and tissue factor 
(extrinsic) activated thromboelastography27. In this 
study R and K time (similar to CT and CFT) were short-
er and maximum amplitude (similar to MCF) was 
stronger after longer storage times. Although the de-
crease in FIBTEM CT and/or INTEM CFT may have 
been caused by the administered TXA as described 
above, an influence of the longer preanalytical time 
cannot be excluded with the current study and in future 
studies the baseline sample should be taken well before 
administration of TXA. In people, ROTEM values were 
stable for 120 minutes after collection26. However, the 
weakening of the APTEM maximum clot firmness can 
neither be explained by the effect of TXA nor by the 
observed preanalytical differences. 
As a second limitation not all results of the eight dogs 
before TXA were within the in house reference ranges 
(Table 1). The reference values were assessed on a differ-
ent ROTEM machine and slight differences between 
devices have been reported8. The dogs that had results 
outside of the reference range were rather hyper – than 
hypocoagulable. It is therefore unlikely that the abnor-
mal baseline values masked a prothrombotic effect of 
50 mg/kg TXA IV. 
As a third limitation, neither fibrinogen (Clauss), 
thrombocyte count nor thrombocyte function testing 
were performed. However, TXA should theoretically 
only inhibit fibrinolysis by blocking the action of plas-
minogen and all procoagulant effect should be caused 
by decreased fibrinolysis. Furthermore fibrinolysis can-
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not be diagnosed with fibrinogen (Clauss) analysis and 
fibrinogen (Clauss) values correlate closely to MCF 
FIBTEM in dogs4. 
As a forth limitation only the in vitro effects of TXA on 
coagulation were assessed by ROTEM. However, al-
though the study did not concentrate on the assessment 
of thromboembolic side effects in vivo, none of the dogs 
showed an obvious sign of thromboembolic complica-
tions such as tachypnoea or lameness after the admin-
istration of 50 mg/kg IV TXA. 
In future, it needs to be analysed if the administration 
of a high dose of TXA to non-bleeding dogs i.e. as an 
emetic is safe in patients in dogs with diseases common-
ly associated with hypercoagulability. 
Conclusions
The administration of 50 mg/kg TXA IV resulted in 
small changes in ROTEM profiles without inducing a 
hypercoagulable clot. In conclusion, TXA can safely be 
administered to healthy dogs with normal coagulation 
profiles. As an additional finding, APTEM parameters 
measured in the current study do not support the use 
of this test in dogs. 
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Effetto di 50 mg/kg di acido tranexa-
mico per via endovenosa sulla coagu-
lazione determinato mediante trom-
boelastografia rotazionale (ROTEM) 
nei cani di razza Beagle sani. 
Nelle persone, il farmaco antifibrinolitico acido tranexa-
mico riduce l’emorragia e la necessità di prodotti ema-
tici con fibrinolisi normale ed esagerata senza aumenta-
re il numero di eventi tromboembolici. Nei cani, oltre 
alla prevenzione e al trattamento dell’emorragia, dosi 
più elevate di acido tranexamico possono essere utiliz-
zate per indurre il vomito. L’obiettivo di questo studio 
è stato quello di valutare l’effetto di un’alta dose di aci-
do tranexamico sulla coagulazione dei cani Beagle sani. 
È stato condotto uno studio prospettico in otto Beagle 
sani a cui veniva somministrato acido tranexamico per 
uno studio concomitante che valutava diversi antieme-
tici. L’analisi tromboelastografica rotazionale (ROTEM) 
(EXTEM, APTEM, FIBTEM, INTEM) è stata eseguita 
prima e 30 minuti dopo la somministrazione endove-
nosa di 50 mg/kg di acido tranexamico. I parametri 
ROTEM prima e dopo la somministrazione di acido 
tranexamico e tra EXTEM e APTEM sono stati con-
frontati con il test di Wilcoxon dei ranghi con segno 
con misure accoppiate e i dati sono stati presentati come 
mediana (rango). Dopo la somministrazione di acido 
tranexamico, il tempo di coagulazione FIBTEM è di-
ventato significativamente più breve (p=0.03) da 37 s 
(28-124 s) a 33 s (27-40 s) e il tempo di formazione del 
coagulo INTEM è diminuito significativamente 
(p=0.02) da 82 s (47-132 s) a 60 s (43-107 s). Dopo la 
somministrazione dell’acido tranexamico APTEM 
MCF era significativamente più debole (p=0.01) con 45 
mm (30-63 mm) di EXTEM MCF con 55 mm (43-
69 mm) e di APTEM MCF prima dell’acido tranexami-
Effet de 50 mg/kg d’acide tranexa-
mique par voie intraveineuse sur la 
coagulation évaluée par thromboélas-
tométrie rotationnelle (ROTEM) chez 
des chiens Beagle en bonne santé
Chez l’homme présentant une fibrinolyse normale et 
exagérée, l’acide tranexamique, un agent antifibrinoly-
tique, réduit les saignements et le besoin de produits 
sanguins sans augmenter le nombre d’événements 
thromboemboliques. Chez les chiens, en plus de la pré-
vention et du traitement des saignements, des doses plus 
élevées d’acide tranexamique peuvent être utilisées pour 
provoquer des vomissements. L’objectif de cette étude 
était d’évaluer l’effet d’une dose élevée d’acide tranexa-
mique sur la coagulation de chiens Beagle en bonne 
santé.
Un essai prospectif a été mené chez huit Beagles en 
bonne santé recevant de l’acide tranexamique dans le 
cadre d’un essai simultané évaluant différents antiémé-
tiques. Une analyse de la thromboélastométrie rotation-
nelle (ROTEM) (EXTEM, APTEM, FIBTEM, INTEM) 
a été réalisée avant et 30 minutes après l’administration 
intraveineuse de 50 mg/kg d’acide tranexamique. Les 
paramètres ROTEM avant et après l’administration 
d’acide tranexamique et entre EXTEM et APTEM ont 
été comparés au test de rang de Wilcoxon à paires appa-
riées et les données sont présentées sous forme de mé-
diane.
Après administration de l’acide tranexamique, le temps 
de coagulation de FIBTEM est devenu significativement 
plus court (p = 0,03) de 37 s (28-124 s) à 33 s (27-40 s) 
et le temps de formation du caillot INTEM a été signi-
ficativement réduit (p = 0,02) de 82 s (47-132 s) à 60 s 
(43-107 s). Après l’acide tranexamique, APTEM MCF 
était significativement plus faible (p = 0,01) avec 45 mm 
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(30-63 mm) que EXTEM MCF avec 55 mm (43-69 mm) 
et qu’APTEM MCF avant l’acide tranexamique avec 
55 mm (43-69 mm) (p = 0,02). Tous les autres paramètres 
analysés, y compris la lyse maximale, n’ont pas changé 
après l’administration d’acide tranexamique.
L’administration de 50 mg/kg d’acide tranexamique par 
voie intraveineuse a entraîné de légers changements dans 
les profils ROTEM sans induire de caillot hypercoagu-
lable. En conclusion, l’acide tranexamique peut être 
administré en toute sécurité à des chiens en bonne san-
té présentant des profils de coagulation normaux. Autre 
constatation supplémentaire, les paramètres APTEM 
mesurés dans la présente étude n’appuient pas l’utilisa-
tion de ce test chez le chien.
Mots-clés: antifibrinolytique, chien, émétique, acide 
tranexamique, test de coagulation viscoélastique,  
vomissements
co con 55 mm (43-69mm) (p=0.02). Tutti gli altri para-
metri analizzati, compresa la lisi massima, non sono 
cambiati dopo la somministrazione di acido tranexami-
co. La somministrazione di 50 mg/kg di acido tranexa-
mico per via endovenosa ha portato a piccole modifiche 
nei profili ROTEM senza indurre un coagulo trombo-
filo. In conclusione, l’acido tranexamico può essere 
somministrato con sicurezza nei cani sani con profili di 
coagulazione normali. Come ulteriore risultato, i para-
metri APTEM misurati nello studio attuale non suppor-
tano l’uso di questo test nei cani.
Parole chiave: Antifibrinolitico, canino, emetico, acido  
tranexamico, test di coagulazione viscoelastica, vomito
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